1. Core Business & Product Portfolio

Sonoscape's core offerings focus on four major categories of high-end medical devices, with comprehensive supporting services:

Ultrasound Diagnostic Equipment: Color Doppler ultrasound systems, obstetric & gynecologic ultrasound, cardiovascular ultrasound, and endoscopic ultrasound (EUS), widely used in clinical diagnosis, intraoperative monitoring and health screening.

Endoscopic Systems: High-definition (HD) and 4K electronic endoscopes (gastrointestinal, respiratory), therapeutic endoscopy accessories, and domestically pioneered radial array EUS.

Optical Imaging & Minimally Invasive Surgery Devices: 4K rigid endoscopes for surgical use, laparoscopic systems, and vascular ultrasound (IVUS) products.

Vital Signs Monitoring Equipment: Patient monitors and multi-parameter diagnostic devices for primary care and hospital settings.

Value-Added Services: Equipment maintenance, technical support, integrated medical imaging solutions, as well as overseas compliance operation and market support services.

Sonoscape's products serve hospitals at all levels, physical examination centers, and primary healthcare institutions, covering clinical diagnosis, intraoperative monitoring, and health screening across multiple medical fields.

2. History & Milestones

Founded in 2002, the company has continuously made breakthroughs in core technologies and launched a number of domestically pioneering medical devices. It was listed on the ChiNext Board of Shenzhen Stock Exchange in 2017. Since then, it has expanded product lines and global business layout, and launched cutting-edge products such as 4K endoscopes and AI-powered ultrasound screening systems, steadily strengthening its industrial competitiveness.

3. Core Strengths & Achievements

Technological Innovation & R&D Strength: With 20+ years of deep expertise in medical devices, Sonoscape holds massive independent patents, with multiple core technologies reaching international advanced levels. It has LED and participated in formulating national industry standards for medical imaging devices. The company invests ~20% of annual revenue in R&D, with 7 global R&D centers (Shenzhen, Shanghai, Wuhan in China; San Francisco, Seattle in the US; Tuttlingen in Germany; Tokyo in Japan) and 800+ R&D personnel.

Global Market Performance: Sonoscape's products are sold in 170+ countries and regions, with leading market share in both domestic and global markets. It has entered over 90% of tertiary hospitals in China and maintained steady revenue and profit growth, ranking in the first tier of China's medical device industry for consecutive years. In 2025, revenue reached RMB 2.309 billion (up 14.65% YoY), with net profit of RMB 197 million (up 38.54% YoY).

Qualifications & Global Certifications:

National-level High-Tech Enterprise, "Specialized, Refined, Differential, Innovative" Enterprise, and National Enterprise Technology Center.

Products certified by China NMPA, EU CE, and US FDA, widely recognized for quality and compliance in global markets.

4. Development Prospects

Driven by the expanding global healthcare demand and accelerated import substitution of high-end medical devices in China, the company will further focus on medical imaging, increase R&D investment in cutting-edge technologies like artificial intelligence and minimally invasive diagnosis and treatment, optimize global marketing and service networks, and expand domestic and overseas markets. Going forward, it strives to become a world-leading provider of medical imaging solutions and empower the development of global healthcare with innovative technologies.